Plexiform Neurofibroma Treatment Market Report 2026

Plexiform Neurofibroma Treatment Market Overview

• Plexiform Neurofibroma Treatment market size has reached to $1.45 billion in 2025 • Expected to grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Rising Demand For Personalized Medicine Fueling The Growth Of The Market Due To Increasing Focus On Rare-Disease Therapies • Market Trend: Advancements In Targeted Therapies Driving Improved Outcomes In Plexiform Neurofibroma Treatment • North America was the largest region in 2025.

What Is Covered Under Plexiform Neurofibroma Treatment Market?

Plexiform neurofibroma treatment involves medical approaches aimed at managing and controlling the growth of complex nerve sheath tumors. The goal is to reduce symptoms, prevent complications, and improve quality of life by addressing the tumor's impact on surrounding tissues and structures. The main types of plexiform neurofibroma treatments include surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery refers to a branch of medicine that involves the treatment of injuries, diseases, or other health problems through manual and instrumental techniques, typically by making incisions in the body to remove, repair, or investigate tissues or organs. It is used for various indications such as pain management, tumor reduction, and functional restoration for both pediatric and adult patients. It is used by several end users, including hospitals, clinics, and home care settings.

What Is The Plexiform Neurofibroma Treatment Market Growth Forecast?

The plexiform neurofibroma treatment market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to advancements in targeted and precision therapies, increasing clinical research and drug approvals, growing awareness of rare genetic disorders, expansion of pediatric oncology services, integration of personalized treatment planning. Major trends in the forecast period include rising adoption of targeted therapies for tumor control, increasing use of minimally invasive and robotic surgeries, growing focus on pediatric patient-specific treatment approaches, expansion of combination therapy protocols, improved symptom management and quality of life outcomes.

Global Plexiform Neurofibroma Treatment Market Segmentation

1) By Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy 2) By Indication: Pain Management, Tumor Reduction, Functional Restoration 3) By Patient Population: Pediatric, Adult 4) By End User: Hospitals, Clinics, Home Care Settings Subsegments: 1) By Surgery: Open Surgery, Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Laser Surgery 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy) 3) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Plant Alkaloids, Topoisomerase Inhibitors, Miscellaneous Agents, Combination Chemotherapy 4) By Targeted Therapy: Monoclonal Antibodies, Small Molecule Inhibitors, Angiogenesis Inhibitors, Tyrosine Kinase Inhibitors, mTOR Inhibitors, PARP Inhibitors, CDK Inhibitors

What Is The Driver Of The Plexiform Neurofibroma Treatment Market?

The increasing demand for personalized medicine is expected to propel the growth of the plexiform neurofibroma treatment market going forward. Personalized medicine refers to the customization of medical treatment based on a patient’s genetic profile and molecular markers, enabling therapies that are highly specific to individual tumor biology and genetic mutations. The rise in personalized medicine is driven by the growing focus on rare-disease patients and mutation-targeted therapies. Increasing demand for personalized medicine is accelerating advancements in Plexiform Neurofibroma treatment by fostering the development of targeted therapies and precision-based approaches that tailor interventions to the unique genetic and molecular profiles of individual patients, ultimately improving efficacy, minimizing side effects, and addressing the heterogeneity of tumor presentation. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the U.S. FDA approved 26 new personalized treatments, including 20 molecular entities and six gene- or cell-based therapies, with 16 of these aimed at rare-disease patients more than double the 6 approvals in 2022. Therefore, the increasing demand for personalized medicine are driving the growth of the plexiform neurofibroma treatment industry.

Key Players In The Global Plexiform Neurofibroma Treatment Market

Major companies operating in the plexiform neurofibroma treatment market are SpringWorks Therapeutics, AstraZeneca, Roche Holding AG, Novartis AG, Bayer AG, Eli Lilly and Company, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., AbbVie Inc., Merck KGaA, Ipsen Pharma, Bristol-Myers Squibb, BioMarin Pharmaceutical Inc., Sangamo Therapeutics, Recursion Pharmaceuticals, Day One Biopharmaceuticals, BridgeBio Pharma, Loxo Oncology (Eli Lilly subsidiary), Blueprint Medicines, Kura Oncology, Exelixis Inc., Natera Inc., Amgen Inc., Taiho Pharmaceutical Co. Ltd., Zai Lab Limited, Innovent Biologics, BeiGene Ltd., Deciphera Pharmaceuticals, Cullinan Oncology

Global Plexiform Neurofibroma Treatment Market Trends and Insights

Major companies operating in the plexiform neurofibroma treatment market are focusing on developing advanced solutions, such as small-molecule inhibitors, to enhance treatment outcomes. Small-molecule inhibitors are low-weight compounds designed to interfere with specific proteins or enzymes to block abnormal cellular processes. For instance, in February 2025, SpringWorks Therapeutics, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Gomekli, an oral small-molecule MEK inhibitor. Gomekli is indicated for the treatment of adults and children aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that cannot be completely removed by surgery. Clinical trials showed that 41% of adults and 52% of pediatric patients experienced a confirmed reduction in tumor size. The average decrease in tumor volume was 41% in adults and 42% in children. Additionally, responses lasting at least 12 months were observed in 88% of adults and 90% of children, with nearly half of all patients in both groups maintaining their response for more than 24 months.

What Are Latest Mergers And Acquisitions In The Plexiform Neurofibroma Treatment Market?

In April 2025, Merck Group, a Germany-based pharmaceutical company, acquired SpringWorks Therapeutics for $3.4 billion. With this acquisition, Merck aims to immediately enhance its healthcare business revenues, accelerate mid- to long-term growth, and strengthen its footprint in the U.S. market. The deal significantly expands Merck’s portfolio in rare tumors and rare diseases, as SpringWorks adds two FDA-approved therapies Ogsiveo, for the treatment of desmoid tumors, and Gomekli, for neurofibromatosis type 1-associated plexiform neurofibromas. SpringWorks Therapeutics is a US-based biopharma company specializing in plexiform neurofibroma treatment.

Regional Insights

North America was the largest region in the plexiform neurofibroma treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Plexiform Neurofibroma Treatment Market?

The plexiform neurofibroma treatment market consists of revenues earned by entities by providing services such as genetic testing, clinical evaluation, multidisciplinary care coordination, and clinical trial management. The market value includes the value of related goods sold by the service provider or included within the service offering. The plexiform neurofibroma treatment market also includes sales of tumor monitoring kits, genetic testing kits, clinical decision support tools, and rehabilitation aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plexiform Neurofibroma Treatment Market Report 2026?

The plexiform neurofibroma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plexiform neurofibroma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.